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A fundamental system of cellular energy homeostasis
regulated by PGC-1
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Contributed by Bruce M. Spiegelman, March 23, 2007 (sent for review February 23, 2007)
Maintenance of ATP levels is a critical feature of all cells. Mito-
chondria are responsible for most ATP synthesis in eukaryotes. We
show here that mammalian cells respond to a partial chemical
uncoupling of mitochondrial oxidative phosphorylation with a
decrease in ATP levels, which recovers over several hours to control
levels. This recovery occurs through an increased expression of the
transcriptional coactivator peroxisome proliferator-activated
receptor-coactivator 1 (PGC-1) and mitochondrial genes. Cells
and animals lacking PGC-1 lose this compensatorymechanismand
cannot defend their ATP levels or increase mitochondrial gene
expression in response to reduced oxidative phosphorylation. The
induction of PGC-1 and its mitochondrial target genes is triggered
by a burst of intracellular calcium, which causes an increase in
cAMP-response-element-binding protein and transducer of regu-
lated cAMP-response-element-binding proteins actions on the
PGC-1 promoter. These data illustrate a fundamental transcrip-
tional cycle that provides homeostatic control of cellular ATP. In
light of this compensatory system that limits the toxicity of mild
uncoupling, the use of chemical uncoupling of mitochondria as a
means of treating obesity should be re-evaluated.
mitochondria  uncoupling
M itochondria are responsible for producingmost of the ATPneeded for energy-requiring reactions in eukaryotic cells
(1). In the process of oxidative phosphorylation (OXPHOS), a
proton gradient across the inner mitochondrial membrane is
coupled to the synthesis of ATP by the F1F0ATPase at complex
V. Mitochondrial metabolism is dynamic and can be modulated
in response to external stimuli. For example, the -adrenergic
pathway is activated upon cold exposure in mice, which causes
brown adipose tissue to shift toward more uncoupled respiration
(2–4). In uncoupled respiration, the protons pumped into the
intermembrane space leak back into the mitochondrial matrix,
bypassing ATP production and generating heat.
Mitochondria themselves can elicit intracellular signaling path-
ways that alter nuclear gene expression, mitochondria number, and
function (5, 6). This signaling process is referred to as retrograde
signaling.Retrograde signaling has beenwell studied in the budding
yeast, Saccharomyces cerevisiae. Yeast lacking mtDNA show in-
creased expression of many genes important for the function of
mitochondria, such as citrate synthase, and several proteins have
been identified in yeast that regulate retrograde signaling (7). Little
is known about the regulatory proteins involved in the mechanisms
of retrograde signaling in higher eukaryotes. Similarly, how and to
what extent higher eukaryotic cells can defend their ATP levels
during chronic challenges has not been extensively explored.
Peroxisome proliferator-activated receptor-coactivator 1
(PGC-1) was first identified as a cold-inducible transcriptional
coactivator of peroxisome proliferator-activated receptor  that can
activate a program of adaptive thermogenesis (8). PGC-1 has
since been shown to be a dominant regulator of mitochondrial
function, biogenesis, and respiration inmany tissues (9–13). Ectopic
expression of PGC-1 in white adipocytes increases cellular respi-
ration and genes important for mitochondrial function, such as
uncoupling protein 1, cytochrome c (Cyt c), and Cyt c oxidase
subunit II (COX II). Furthermore, increased expression of PGC-1
increases mitochondrial volume density and cristae density (14).
PGC-1 also can activate a program of fiber-type switching in
skeletal muscle, including increased mitochondrial content and the
expression of myofibrillar proteins characteristic of type 1 and type
2amuscle fibers (15). PGC-1, the closest homolog of PGC-1, has
also been shown to regulate mitochondrial biogenesis and respira-
tion in cells and transgenic animals (13, 16, 17).
2,4-Dinitrophenol (DNP), a chemical mitochondrial uncoupler,
was widely used in the 1930s as a treatment for obesity (18–20).
Mild doses were amazingly effective, often causing rapid loss of
adiposemass and bodyweight.While unregulated use led to reports
of toxicity and even death, it was not as lethal as might have been
expected for a compound that disrupted OXPHOS. This tolerance
indicates that cells can sustain mild chemical uncoupling, perhaps
by using an energy compensatory mechanism. In the present study,
we have investigated whether uncoupling of the mitochondrial
membrane potential could activate a compensatory pathway con-
trolling ATP homeostasis. Indeed, chemical uncoupling increases
the expression of PGC-1 and PGC-1, as well as the expression of
several target mitochondrial genes. Studies using PGC-1 null cells
and animals indicate that PGC-1 is required for the induction of
mitochondrial gene expression, recovery of ATP levels, and cell
survival. Together, these data illustrate a fundamental system of
energy homeostasis whereby cells and tissues use PGC-1 to
recover energy balance and also demonstrate that a powerful
compensatory system exists that limits the toxicity of mild
uncoupling.
Results
Chemical Uncoupling Causes a Transient Drop in ATP Levels. To
examine whether and how mammalian cells might adapt to the
chemical uncoupling of mitochondrial OXPHOS, we measured
ATP levels and cell death in fibroblasts treated with the chemical
mitochondrial uncoupler carbonyl cyanide p-(trifluromethoxy)
phenyl hydrazone (FCCP) (21). Perhaps surprisingly, fibroblasts
treatedwith up to 200MFCCP for 16 h remained 98%viable (Fig.
1A), although viability decreased to80% in the cells treated with
200MFCCP for 24 h. Treatment of fibroblasts with FCCP caused
a 25% in ATP levels at 30 min of treatment (Fig. 1B), but this drop
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was transient, as ATP levels later recovered to those of the
untreated cells. We also examined the amount of lactate produced
during this experiment. Over 24 h, cells treated with FCCP secreted
four times more lactate than the untreated cells (Fig. 1C). This
finding suggests that glycolytic metabolism helps cells withstand a
decrease in OXPHOS caused by chemical uncoupling.
We asked whether this mitochondrial uncoupling had any affect
on mitochondrial density by using electron microscopy to quantify
the volume of mitochondria in cells treated with FCCP. Fibroblasts
were exposed to 0 or 25 M FCCP for 72 h, and mitochondrial
volume density was measured as described (14, 22). Fibroblasts
treated with FCCP displayed a 1.8-fold higher mitochondrial vol-
ume than control cells and higher levels of Cyt c protein [Fig. 1D
and supporting information (SI) Fig. 7], suggesting that chronic
uncoupling induces a compensatory program that not only helps to
recover ATP levels, but alters mitochondrial density well.
Partial Chemical Uncoupling of Mitochondria Induces PGC-1, PGC-1,
and Mitochondrial OXPHOS Genes. To determine whether changes in
the expression of genes related to mitochondrial function accom-
pany the metabolic alterations seen in cells treated with FCCP, we
measured the mRNAs encoding the PGC-1 coactivators, powerful
regulators of mitochondrial gene expression, and expression of
genes of the electron transport system. Using real-time PCR, we
observed an induction of mRNAs encoding for Cyt c, COX II,
F1-ATPase, and nuclear respiratory factor 1 (NRF-1). In addition,
PGC-1 and PGC-1 mRNA increased 7.5- and 5.5-fold, respec-
tively, upon treatment with FCCP for 16 h (Fig. 2A). In extended
treatment with FCCP for 72 h, mRNA for PGC-1 and PGC-1
was elevated 4-fold, and the mRNAs encoding Cyt c, COX II,
F1-ATPase, andNRF-1 were also significantly elevated relative to
vehicle-treated cells (Fig. 2B). To determine whether a different
mitochondrial uncoupler could also increase these genes, fibro-
blasts were treatedwithDNP. Sixteen hours of treatment withDNP
increased PGC-1 and PGC-1 mRNA 7-fold; mRNAs for Cyt
c, COX II, F1-ATPase, and hexokinase were similarly induced (SI
Fig. 8). These data indicate that chemical uncoupling of the
mitochondrial electron transport chain induces genes of mitochon-
drial OXPHOS and mRNA encoding the PGC-1 coactivators.
PGC-1 Is Required for the Induction of Mitochondrial Gene Expres-
sion, Recovery of ATP Levels, and Cell Survival. We investigated
whether the induction of PGC-1 is required for the uncoupling-
mediated induction of the compensatory metabolic program. Im-
mortalized preadipocytes isolated from the brown fat of WT and
PGC-1/ mice (23) were treated with FCCP for 16 h. Similar to
what was seen in fibroblasts, this treatment induced a significant
increase in the expression of mRNAs encoding PGC-1, PGC-1,
and several genes of the electron transport system (Fig. 2C).
Strikingly, cells lacking PGC-1 had an almost complete ablation of
the induction of PGC-1 andOXPHOS genes, which indicates that
PGC-1 is almost absolutely required for the induction of the
mitochondrial electron transport genes induced by partial mito-
chondrial uncoupling.
To determine whether PGC-1 contributes to cell survival
during reduced mitochondrial function, a cytotoxicity assay was
used to examine cell viability after treatment with FCCP in both the
Fig. 1. Chemical uncoupling induces multiple metabolic changes. (A) Cells
were treated with 0, 25, 50, 100, or 200 M FCCP for 16 or 24 h, and viability
was measured by using the LDH assay (P 0.01 compared with untreated cells
at 24 h). (B) ATP levels were measured after fibroblasts were treated with 0 or
50 M FCCP for 0, 2, 8, 16, or 24 h (P 0.01 compared with the untreated cells
at 0.5 h). (C) Lactate was measured after fibroblasts were treated with 0 or 50
M FCCP for 2, 8, 16, or 24 h (P 0.01 compared with the untreated cells). (D)
Mitochondrial volume density in cells treated with 0 and 25 M FCCP for 72 h
(P  0.01).
Fig. 2. Chemical uncoupling induces OXPHOS genes and the PGC-1 coacti-
vators. (A) Fibroblasts were treated with 0 or 50 M FCCP for 16 h. RNA was
measured by using real-time PCR (all points are significant except for tubulin,
P 0.01). (B) The experiment inAwas repeated, but cells were treated for 72 h
with 0 or 25 M FCCP (all points are significant except for tubulin and
hexokinase, P 0.01). (C) WT and PGC-1/ preadipocytes (KO) were treated
with 0 or 50 M FCCP for 16 h, and mRNAs were measured. The PGC-1
measurement represents exon 2, which is still present in the KO cells (P 0.05
compared with the WT FCCP-treated cells). (D) WT and PGC-1 KO preadipo-
cytes were treated with 0, 25, 50, 100, and 200M FCCP for 16 or 24 h. Viability
was measured by using the LDH cytotoxicity assay (P 0.01 compared with the
WT FCCP-treated cells). (E) ATP levels in the WT and PGC-1 KO cells were
measured after treatment with 50 M FCCP (P 0.02 compared with the WT
FCCP-untreated cells at 16 h). (F) Lactate levels in the media of WT and KO cells
treated with 200 M FCCP for the were measured (P  0.005 compared with
the WT FCCP-treated cells at 16 h).
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WTandPGC-1 null cells.Whereas theWTcells showed very little
death with up to 200 M FCCP at either time point, the PGC-1
null cells showed a very substantial loss of viability (Fig. 2D). Only
80% and 60% of the mutant cells survived 100 and 200 MFCCP,
respectively, after 16 h. After 24 h, only 30% of the mutant cells
survived 200 MFCCP compared with 85% of control cells. Thus,
PGC-1 contributes substantially to the ability of these cells to
survive partial uncoupling of the electron transport chain.
We next studied whether PGC-1 plays a role in the recovery of
theATP levels seen after treatment with FCCP (Fig. 1B). BothWT
and PGC-1/ cells displayed an initial 20% decrease in ATP
levels (Fig. 2E). After 16 h, theWT cells completely recovered their
ATP levels to those of the untreated cells, whereas the PGC-1/
cells could not restore their ATP levels. By 16 h, the ATP levels in
the mutant cells were 68% of the ATP levels in the untreated
cells. In the same experiments, we measured lactate levels pro-
duced. After 16 h, the FCCP-treated WT cells secreted approxi-
mately three times more lactate than the untreated WT cells (Fig.
2F). The untreated PGC-1/ cells secreted significantly more
lactate than both the treated and untreated WT cells, which was
also true of the FCCP-treated PGC-1/ cells. These experiments
together indicate that the recovery of ATP levels and cell survival
seen after chronic treatment with FCCP requires PGC-1.
Intracellular Calcium Plays a Critical Role in the PGC-1 Pathway.
Mitochondria store significant quantities of calcium, andmitochon-
drial uncoupling is known to cause an increase in intracellular
calcium ([Ca2]i) levels (6, 24–28). These data are of particular
interest because the induction of PGC-1 in other contexts has been
shown to be regulated by components of the calcium signaling
pathways (17, 29). 1,2-Bis(2-aminophenoxy)ethane-N,N,N,N-
tetraacetate (BAPTA), a membrane soluble calcium chelator (30),
has been shown to block the rise in [Ca2]i caused by the uncoupling
agent FCCP (24, 31–33). Using the calcium-sensitive dye Fura-2
(34), we observed a 3-fold increase in [Ca2]i when fibroblasts were
treated with FCCP (Fig. 3A). Pretreatment of cells with BAPTA
largely suppressed this rise in [Ca2]i (Fig. 3B). To determine
whether reducing the FCCP-mediated [Ca2]i rise with BAPTA
could block the expression of PGC-1 and the other OXPHOS
genes, fibroblasts were pretreated with BAPTA before treatment
with FCCP. Indeed, the rise in PGC-1 mRNA caused by FCCP
was completely blocked (Fig. 3C); the increases in the mRNAs for
Cyt c, COX II, and F1-ATPase caused by FCCPwere also ablated.
To test whether compounds that increased [Ca2]i levels had the
same effect on PGC-1 and mitochondrial gene expression as
mitochondrial uncouplers, we treated fibroblasts for 16 h with the
calcium ionophoreA23187.As seen after treatmentwithFCCP, the
mRNAs for PGC-1, PGC-1, and the mRNAs for Cyt c, COX II,
F1-ATPase, and NRF-1 all were increased (Fig. 3D). These data
strongly suggest that altered calcium flux is a key component in the
mechanism of this mitochondrial retrograde pathway regulated by
PGC-1.
AMP-activated protein kinase (AMPK) is activated during low
energy conditions, particularly when the ratio of AMP/ATP in-
creases (35). AMPK activation is also known to induce PGC-1
gene expression inmuscle (36, 37). As expected, AMPK is activated
upon treatment with FCCP (Fig. 4B) (33, 38). To investigate the
role of AMPK in the uncoupling-induced homeostatic pathway, we
inhibited AMPK and looked at the subsequent induction of
PGC-1 and OXPHOS gene expression. Fibroblasts were pre-
treated with the AMPK inhibitor compound C for 1 h, followed by
treatment with FCCP. Whereas FCCP alone induced PGC-1,
PGC-1, and Cyt c mRNA levels, the addition of compound C
almost completely blocked the further induction of those genes
(Fig. 4A). However, pretreatment of cells with BAPTA blocks the
activation of AMPK (Fig. 4B), suggesting that calcium signaling is
upstream of the activation of AMPK by FCCP.
Fig. 3. The induction of PGC-1, PGC-1, and OXPHOS genes requires
increased [Ca2]i levels. (A) Fibroblasts were loaded with Fura-2, and [Ca2]i
levels were measured (34, 54) as 50M FCCP was added. (B) [Ca2]i levels were
measured as in A first with the addition 10 M BAPTA and the subsequent
addition of FCCP. (C) Fibroblasts were pretreated for 1 h with 0 or 10 M
BAPTA followed by 16 h of treatment with 0 or 50 M FCCP, and mRNAs were
measured (P  0.01 compared with the FCCP-treated cells). (D) Fibroblasts
were treated with 0 or 5 M A23187 for 16 h (all points are significant except
for tubulin, P  0.01), and mRNAs were measured.
Fig. 4. AMPK and CREB are involved in the mechanism inducing PGC-1. (A)
Fibroblasts were pretreated for 1 h with 0 or 25M compound C (CC) followed
by 16 h of treatment with 0 or 50 M FCCP. mRNAs were measured (P 0.02
compared with FCCP-treated cells). (B) Fibroblasts were treated as in Fig. 3C.
Western blots were used to measure protein levels. (C) PGC-1 promoter
constructs with a luciferase reporter containing mutations in the MEF or CRE
site were transfected into fibroblasts (PGC-1 WT is the unmutated PGC-1
2-kb promoter), then treated with FCCP. Luciferase units were normalized to
-galactosidase and to the cells treated with 0 M FCCP (P 0.01). (D) ACREB
was cotransfected with the PGC-1 2-kb promoter into fibroblasts. The cells
were treated with FCCP, and luciferase units were measured and normalized
as in C (P  0.01).








Involvement of cAMP-Response-Element-Binding Protein (CREB) in the
Induction of the PGC-1 Promoter. To elucidate the mechanism of
this energy cycle further, we investigated the cis- and trans-acting
factors that play a role in the induction of the PGC-1 gene upon
chemical uncoupling. Activity of a promoter segment containing 2
kb of the 5 flanking region of the PGC-1 promoter driving a
luciferase gene (29) was induced 3-fold upon treatment with FCCP
(Fig. 4C). Transfections of the PGC-1 promoter harboring mu-
tations in the MEF2 and CREB binding sites were analyzed.
Promoter constructs with a mutation in the MEF2 binding site
showed no difference in activity compared with the WT PGC-1
promoter (Fig. 4C). However, mutation of the CREB binding site
(39) resulted in an almost complete ablation of the increase in the
PGC-1 promoter activity in response to FCCP.
To investigate the role of the transcription factor CREB in the
FCCP-mediated induction of the PGC-1 promoter, we examined
the induction of the WT 2-kb PGC-1 promoter in the presence of
a dominant-negative version of the CREB protein (ACREB) (40).
ACREB, a fusion of an acidic amphipathic domain and the leucine
zipper dimerization domain of CREB, heterodimerizes with en-
dogenous CREB and prevents it from binding to DNA. ACREB
completely blocked the induction of the PGC-1 promoter ob-
served upon treatment with 50 M FCCP (Fig. 4D). Typically
CREB protein requires activation by phosphorylation, often at
Ser-133. Fig. 4B shows that treatment with FCCP increases the
regulatory Ser-133 phosphorylation of CREB. However, BAPTA,
which blocks the induction of PGC-1mRNA and OXPHOS gene
expression, does not block the phosphorylation of CREB. These
data together suggest a required role forCREB in the control of the
PGC-1 promoter, but also suggest other regulated steps in this
pathway must exist.
Involvement of Transducer of Regulated CREB Proteins (TORCs) in the
Regulation of PGC-1. We sought to identify other factors in the
calcium signaling pathway that were sensitive to BAPTA. Recently,
the TORC coactivators have emerged as important regulators of
CREB-dependent transcription, irrespective of the phosphoryla-
tion state of CREB (41–48). Given this and their involvement in
calcium signaling pathways (43, 44), the TORCs seemed to be
plausible regulators in the pathway by which uncoupling induces
PGC-1. To determine whether TORCs are involved in the
PGC-1 energy cycle, fibroblasts were treated with FCCP. TORC1
mRNA increased 1.6-fold, TORC2 mRNA increased 2.1-fold, and
TORC3 mRNA increased 4.2-fold (Fig. 5A); pretreatment with
BAPTA completely blocked the induction of all three TORC
mRNAs. To determine whether TORCs play a role in the FCCP-
mediated induction of the PGC-1 promoter, we measured the
induction of the WT 2-kb PGC-1 promoter in the presence of a
dominant-negative version of TORC (43). The dominant-negative
TORC protein (T1–44eGFP) is a fusion protein of the conserved
CREB binding domain of TORC1 and eGFP. T1–44eGFP has
been shown to block the activation of CREB by TORC1, TORC2,
and TORC3 (43). In the absence of T1–44eGFP, the PGC-1
promoter was induced 9.5-fold upon treatment with FCCP (Fig.
5B). However, T1–44eGFP completely blocked the FCCP-
mediated induction of the PGC-1 promoter, suggesting strongly
thatTORCs are required for the induction of thePGC-1promoter
under these conditions.
In a similar experiment, preadipocytes constitutively expressing
T1–44eGFP were treated with FCCP for 16 h, and expression of
several mitochondrial genes was subsequently measured. Control
cells showed a 4.6-fold increase in PGC-1mRNA and increases in
PGC-1, Cyt c, COX II, F1-ATPase, andmitochondrial transcrip-
tion factorA (TFAM)mRNAs (Fig. 5C). However, cells expressing
T1–44eGFP had a blunted induction of mRNAs for all of these
genes, again suggesting that TORCs are required for the PGC-1
energy cycle induced by uncoupling.
ChIP was used to measure the association of TORCs with the
endogenous PGC-1 promoter in the presence of FCCP and
Fig. 5. TORC plays a critical role in the uncoupling-mediated induction of PGC-1 and mitochondrial genes. (A) Fibroblasts were treated as described in Fig.
3C (P  0.01 compared with the FCCP-treated samples), and mRNAs for TORC1, TORC2, and TORC3 were measured. (B) Fibroblasts were transfected with the
PGC-1 2-kb promoter, cotransfected with T1–44eGFP, and then treated with FCCP. Luciferase units were normalized to the cells treated with 0 M FCCP (P
0.005). (C) Preadipocytes constitutively expressing T1–44eGFP or the eGFP control were treated with either 0 or 50 M FCCP for 16 h, and mRNAs were measured
(P 0.01 compared with FCCP-treated control cells). (D) ChIP was used to measure phospho-CREB protein and TORC protein bound to the PGC-1promoter upon
treatment with FCCP. Fibroblasts were treated as described in Fig. 3C. Cells were cross-linked, and protein–DNA complexes were harvested by using phospho-CREB
or PAN-TORC antibodies. The amount of PGC-1 promoter was then quantified by using PCR and real-time PCR with PGC-1-specific primers (P  0.02).
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BAPTA. Fibroblasts were pretreated with BAPTA, followed by
treatment with FCCP. DNA was immunoprecipitated by using an
anti-phospho-CREB or anti-PAN TORC antibody, and the pres-
ence of the PGC-1 promoter was quantified by PCR and real-time
PCR with PGC-1 promoter-specific primers. FCCP treatment
increased the amount of phospho-CREB and TORC associated
with the PGC-1 promoter by1.8- and 2.5-fold, respectively (Fig.
5D). Pretreatment with BAPTA reduced the amount of phospho-
CREB to 1.4-fold; this same treatment, however, completely
blocked the association of TORCs with the PGC-1 promoter.
These results indicate that the uncoupling-mediated association of
TORCs with the PGC-1 promoter is BAPTA-sensitive and can at
least partly explain the mechanism by which the uncoupling of
OXPHOS induces PGC-1.
Uncoupling Induces the PGC-1 Energy Cycle in Vivo. To determine
whether chemical uncoupling of mitochondria in vivo also increases
the expression levels of PGC-1 and the OXPHOS genes, WT and
skeletal muscle-specific PGC-1 knockout mice were treated with
50 mg/kg DNP for 5 h. In the muscle of WT mice, DNP increased
the expression of PGC-1 and PGC-1 mRNA 2.5- and 1.4-fold,
respectively, in addition to Cyt c, COX II, F1-ATPase, and TFAM
mRNA (Fig. 6A). The mice lacking skeletal muscle PGC-1 had a
lower basal level expression of those genes and completely failed to
induce PGC-1, Cyt c, COX II, F1-ATPase, and TFAM in
response to DNP. At the concentrations used, there was a trend
toward 10% lower ATP levels in the DNP-treated muscles in mice
lacking skeletal muscle PGC-1, but it fell just below the level of
significance (data not shown). Importantly, the genes for PGC-1,
PGC-1, and theOXPHOSgenes were induced in the livers of both
WTandmuscle-specific knockoutmice treatedwithDNP (Fig. 6B).
Furthermore, the mRNA expression levels of PGC-1, PGC-1,
Cyt c, COX II, and TFAM all were significantly elevated in white
adipose tissue as well (data not shown). In brown adipose tissue,
only PGC-1 and TFAM were elevated (data not shown). This
result indicates that partial mitochondrial uncoupling in vivo in-
duces the genes of OXPHOS, and this response requires the
PGC-1 coactivator.
Discussion
We show here that cells have a finely tuned homeostatic
mechanism to compensate for chronic alteration of the electro-
chemical gradient across the inner membrane. Perturbation of
this gradient by chemical uncouplers results, as expected, in a
drop in ATP levels. However, cells recover over several hours to
attain their original ATP concentrations. This compensatory
mechanism is driven mainly by the induction of PGC-1mRNA,
which then stimulates a rise in PGC-1 and an increase in both
mitochondrial gene expression and mitochondrial volume per se.
That this mechanism is crucial to the basic survival of cells is
illustrated by the cell death and loss of ATP levels that results
when PGC-1/ cells are challenged with chemical uncoupling.
These data also illustrate that increased glycolysis cannot pro-
vide sufficient production of ATP because PGC-1/ cells
actually have a greater rate of glycolysis than control cells in
response to uncoupling, but fail to defend their ATP levels.
It is important to note that while some individual components of
this pathway have been described in other contexts, such as the
release of calcium upon mitochondrial uncoupling (6, 24–28) and
the role of TORC proteins on the PGC-1 promoter (47), the
merging of these various individual components into a highly
integrated regulatory system has not been previously described to
our knowledge. Moreover, the striking ability of this system to
precisely maintain cellular ATP levels strongly suggests the physi-
ological relevance of this pathway.
The PGC-1 mitochondrial compensatory mechanism appears
to be triggered by an early rise in [Ca2]i levels, which may be
further amplified by the release of calcium from the endoplasmic
reticulum.Blocking this initial rise in [Ca2]i withBAPTA stops the
induction of PGC-1 completely and also blocks the increases in
OXPHOS gene expression. Although AMPK is almost certainly an
important player in this mitochondrial system, calcium appears to
be the dominant pathway, because the activation of AMPK ob-
served here also depends on the early rise in [Ca2]i levels. That
AMPK can be activated by increases in [Ca2]i has also been
observed by others (33, 49–51). But clearly, both signal transduction
pathways, calcium and AMPK, are required for full induction of
PGC-1.
Activated CREB has proven to be an important regulator of the
PGC-1 promoter in liver and muscle (17, 29, 39). Although the
mitochondrial uncoupling performed in these studies leads to a
great increase in phosphorylation of CREB on Ser-133, it is also
clear from the BAPTA studies that this phosphorylation is not
sufficient to trigger a rise in PGC-1 levels. TORCs, identified
recently as important modulators of both CREB function and
PGC-1 gene expression (41–48), are induced by chemical uncou-
pling and absolutely require increased [Ca2]i levels. Hence, a
substantial part of the induction of PGC-1 that triggers this
homeostatic mechanism depends on both CREB and the TORC
proteins. Activated AMPK is also required for the induction of
PGC-1 and mitochondrial gene expression (52). Paradoxically,
AMPK has been shown to inhibit TORC2 via preventing nuclear
import (45, 46). The role of AMPK on the other TORC proteins
and PGC-1 function itself remains to be determined.
Finally, these results strongly suggest a re-evaluation of the
potential for using chemical uncoupling as a therapeutic approach
to human obesity. Seventy years ago, DNP was widely used to treat
obesity (18–20). Unfortunately, its over-the-counter accessibility
led to uncontrolled use and reports of toxicity and death, so
chemical uncoupling of mitochondria was effectively eliminated as
a plausible means of treating obesity. However, mild chronic doses
had been remarkably effective and, surprisingly, were much less
toxic than might have been expected for a compound that uncou-
pled OXPHOS. Some of the relatively low toxicity of DNP may be
explained by increases in cellular glycolysis and increased electron
transport because of altered ADP/ATP ratios, but it is highly likely
that the chronic mitochondrial homeostatic mechanisms described
here come into play. Fig. 6 shows that these mechanisms exist in
muscle and liver of mice, and it is highly likely that they exist in
tissues of humans. Mild, but chronic, treatment with mitochondrial
uncouplers should cause increased energy expenditure and oxygen
consumption while causing little or no change in ATP levels. This
old, but very simple, idea for treating human obesity should be
revisited with an eye to the molecular compensatory mechanism
revealed here.
Materials and Methods
Reagents.FCCP,DNP, andBAPTAwere obtained fromSigma (St.
Louis, MO). Compound C and A23187 were from Calbiochem
Fig. 6. The uncoupling-mediated induction of mRNA for PGC-1, PGC-1,
and mitochondrial genes occurs in vivo. (A and B) WT and muscle-specific
PGC-1/ female mice were injected with either saline or 50 mg/kg DNP.
Skeletal muscle (A) and liver (B) were harvested after 5 h (P 0.01 compared
with the WT DNP-treated mice, n  8).








(San Diego, CA). Antibodies were from Cell Signaling (Danvers,
MA) except for anti-Pan TORC (Calbiochem). The 2-kb PGC-1
promoter and promoter mutants have been described (29).
ACREB was provided by Charles Vinson (40) (National Institutes
of Health, Bethesda, MD). The dominant-negative TORC
(T1–44eGFP) and control (eGFP) were provided by Novartis
(Basel, Switzerland) (43). Immortalized preadipocytes from
PGC-1WT and null mice (23, 53) and preadipocytes expressing
T1–44eGFP were provided by Marc Uldry (Dana–Farber Cancer
Institute).
Cell Culture, Transfection, and ChIP. 10T 1/2 fibroblasts were grown
in DMEM (10% FBS). Immortalized preadipocytes from PGC-1
WT and / mice were cultured in DMEM (20% FBS). For the
reporter gene assays, cells were transfected overnight with Super-
Fect (Qiagen, Valencia, CA) and treated with FCCP for 24 h.
Luciferase activity was normalized to -galactosidase (Promega,
Madison, WI), and then compared with the empty pGL3basic
vector. PGL3basic vector, pSV vector, and eGFP served as the
controls for thePGC-1 2-kb promoter,ACREB, andT1–44eGFP,
respectively. ChIP was performedwith a ChIP-IT kit (ActiveMotif,
Carlsbad, CA).
Analysis of Gene Expression. RNA was isolated by using TRIzol
(Invitrogen, Carlsbad, CA) and measured by using iSCRIPT and
SYBRGreen (Bio-Rad, Hercules, CA). mRNA levels were nor-
malized to actin mRNA, and then relative mRNA levels were
determined by using the Ct.
Electron Microscopy, Lactate, ATP, and Viability Measurements. ATP
levels were measured by using the ATP Determination Kit (In-
vitrogen). Lactate in the media was quantified with Lactate Re-
agent (Trinity Biotech, Bray, Ireland). Viability was measured by
using the LDH cytotoxicity kit (Roche, Indianapolis, IN). Electron
microscopy was performed, and mitochondrial volume density was
measured as described (14, 22).
Calcium Measurements. Fura-2 ratios were used to calculate [Ca2]
as described (34, 54). For the measurements, EGTA was added to
chelate the extracellular calcium. FCCPwas then added followed by
digitonin and EGTA/Tris for calibration. When BAPTA was used,
it was added before the addition of FCCP.
Animal Experiments. All animal experiments were performed ac-
cording to a protocol approved by the Institutional Animal Care
andUseCommittee.Mice (see SI Text) were injectedwith 50mg/kg
DNP (90% saline, 10% DMSO solution) or 0 mg/kg DNP (90%
saline, 10% DMSO solution). Mice were killed after 5 h.
Statistical Analysis. Results are expressed as SD. Two-tailed
Student’s t tests were used to determine P values.
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